S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NASDAQ:PHIO

Phio Pharmaceuticals - PHIO Stock Forecast, Price & News

$0.74
-0.03 (-3.90%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.74
▼
$0.77
50-Day Range
$0.65
▼
$0.79
52-Week Range
$0.62
▼
$2.42
Volume
179,833 shs
Average Volume
119,017 shs
Market Capitalization
$10.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Phio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
710.7% Upside
$6.00 Price Target
Short Interest
Healthy
0.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Phio Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
38.20%
From $0.89 to $1.23 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

361st out of 1,135 stocks

Pharmaceutical Preparations Industry

178th out of 557 stocks

See Top Rated MarketRank™ Stocks Here
PHIO stock logo

About Phio Pharmaceuticals (NASDAQ:PHIO) Stock

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals Stock Down 3.6 %

NASDAQ:PHIO traded down $0.03 on Friday, reaching $0.74. The company had a trading volume of 179,833 shares, compared to its average volume of 119,017. The stock has a market capitalization of $10.11 million, a P/E ratio of -0.81 and a beta of 1.54. The company's fifty day moving average is $0.71 and its 200 day moving average is $0.83. Phio Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $2.42.

Phio Pharmaceuticals (NASDAQ:PHIO - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.11. On average, research analysts expect that Phio Pharmaceuticals will post 0.89 EPS for the current year.

Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHIO Stock News Headlines

August 11, 2022 | finance.yahoo.com
Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022 | americanbankingnews.com
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and Regeneron Pharmaceuticals (NASDAQ:REGN)
July 11, 2022 | finance.yahoo.com
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner
June 6, 2022 | finance.yahoo.com
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
May 16, 2022 | finance.yahoo.com
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
May 16, 2022 | finance.yahoo.com
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
May 13, 2022 | finance.yahoo.com
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 | finance.yahoo.com
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
May 2, 2022 | finance.yahoo.com
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
May 2, 2022 | finance.yahoo.com
Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors
April 26, 2022 | marketwatch.com
Phio Pharma Shares Drop 10% After Opening Enrollment for PH-762 Trial
April 26, 2022 | seekingalpha.com
Phio begins enrollment in phase 1b trial of PH-762 to treat skin cancer
April 26, 2022 | finance.yahoo.com
Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
April 26, 2022 | benzinga.com
Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma
April 18, 2022 | finance.yahoo.com
Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer
April 11, 2022 | finance.yahoo.com
We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate
April 11, 2022 | seekingalpha.com
Phio down 21% after soaring on Friday on preclinical data for RNAi compound for cancer
April 11, 2022 | finance.yahoo.com
Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism
April 10, 2022 | marketwatch.com
Phio Pharmaceuticals Shares Up on Positive Data for PH-894 Cancer Treatment
April 8, 2022 | uk.investing.com
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
April 8, 2022 | investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.40%
April 8, 2022 | seekingalpha.com
Phio Pharmaceuticals surges 52% on data for RNAi compound for cancer
April 8, 2022 | finance.yahoo.com
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
March 22, 2022 | seekingalpha.com
Phio Pharmaceuticals GAAP EPS of -$1.04 beats by $0.07
March 22, 2022 | finance.yahoo.com
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update
See More Headlines
Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHIO Company Calendar

Last Earnings
11/10/2021
Today
8/14/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHIO
CUSIP
N/A
CIK
1533040
Web
phiopharma.com
Phone
(508) 767-3861
Fax
508-767-3862
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+710.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.83
P/E Growth
N/A
Net Income
$-13,290,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.23%
Return on Assets
-48.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.42
Quick Ratio
8.42

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
505.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.62 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
13,660,000
Free Float
13,576,000
Market Cap
$10.11 million
Optionable
Not Optionable
Beta
1.54

Key Executives

  • Dr. Geert Cauwenbergh Dr. (Age 68)
    Med.Sc., Ph.D., Interim Principal Exec. & Financial Officer and Director
    Comp: $27.5k
  • Ms. Caitlin Kontulis (Age 36)
    VP of Fin. & Admin. and Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PHIO Stock - Frequently Asked Questions

Should I buy or sell Phio Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHIO shares.
View PHIO analyst ratings or view top-rated stocks.

What is Phio Pharmaceuticals' stock price forecast for 2022?

1 equities research analysts have issued twelve-month target prices for Phio Pharmaceuticals' stock. Their PHIO share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 710.7% from the stock's current price.
View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts.

How have PHIO shares performed in 2022?

Phio Pharmaceuticals' stock was trading at $1.00 at the beginning of 2022. Since then, PHIO shares have decreased by 26.0% and is now trading at $0.7401.
View the best growth stocks for 2022 here.

When is Phio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our PHIO earnings forecast.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.03.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.72%), Cetera Investment Advisers (0.55%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $0.74.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals (NASDAQ:PHIO) has a market capitalization of $10.11 million and generates $20,000.00 in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The official website for the company is phiopharma.com. The company can be reached via phone at (508) 767-3861, via email at ir@phiopharma.com, or via fax at 508-767-3862.

This page (NASDAQ:PHIO) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.